Panacea Biotec share news, announcements and annual reports
NSE: PANACEABIOBSE: 531349Pharmaceuticals & BiotechnologySmall Cap
Panacea Biotec Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1996 on BSE, Apr 1996 on NSE
Last close ₹313.25down ₹12.65 (3.88%)BSE ₹312.95
Share price at the NSE close on 30 Oct 2026. Previous close ₹325.90.
30 Oct: open ₹323.05, high ₹325.95, low ₹311.10
52-week range of traded prices to 30 Oct 2026
₹292.40Low, 30 Mar 2026₹647.00High, 9 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,919 Cr1,088th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.30
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −0.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −2.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −3.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 57,86658.2% delivered
Panacea Biotec share news and announcements
875 announcements, routine notices left out, newest first. Page 15 of 18.
Sep 2012
Aug 2012
Jul 2012
12 Jul · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter ended June 30, 2012.
May 2012
19 May · Board meeting
In view of non-availability of profits, the Board of Directors at its meeting held on May 18, 2012 has not recommended any dividend on the Equity Shares of the Company for the financial year ended on March 31, 2012.
Apr 2012
27 Apr · Board meeting
Inter alia, to consider and approve the Audited Financial Results for the Financial Year 2011-12 and the matter pertaining to recommendation / passing over of dividend.
Mar 2012
Feb 2012
Jan 2012
19 Jan · Board meeting
To inter-alia consider and approve the Unaudited Financial Results (provisional) for the quarter and nine months ended December 31, 2011.
Nov 2011
Oct 2011
10 Oct · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter and half-year ended September 30, 2011.
Sep 2011
Aug 2011
Jul 2011
27 Jul · Meeting
Annual General Meeting of the Company has been convened to be held on September 24, 2011. Further, the Register of Members and Share Transfer Books of the Company shall remain closed from September 21, 2011 to September 24, 2011 (both days inclusive) for the purpose of Annual General Meeting and ascertaining the list of members entitled to receive the dividend on Equity Shares, if any, declared at the said meeting. The dividend will be paid/dispatched on October 10, 2011.27 Jul · Results
11 Jul · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter ended June 30, 2011.
Jun 2011
May 2011
13 May · Dividend
Board of Directors at its meeting held on May 13, 2011 has recommended dividend of Re.0.75 (75%) each on Equity Shares of the Company, for the financial year 2010-11. The total amount of dividend payable, if approved by Shareholders in their ensuing Annual General Meeting, shall be Rs.45.9 million, excluding dividend distribution tax.3 May · Board meeting
To inter-alia, consider and approve the Audited Financial Results for the Financial Year 2010-11 and to recommend dividend, if any, on the share capital of the Company.
Apr 2011
Mar 2011
Feb 2011
21 Feb · Limited Review Report
Auditors have conducted the limited review for the un-audited financial results for the quarter ended December 31,2010. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2011
31 Jan · Redemption
At the meeting of the Board of Directors of the Company held on January 28, 2011, the Board has approved the proposed redemption of outstanding Zero Coupon Convertible Bonds worth US$ 36.8 million on their maturity date, i.e. February 14, 2011.17 Jan · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter as well as nine months ended December 31, 2010.
Nov 2010
Oct 2010
19 Oct · Board meeting
To inter-alia, consider and approve the Unaudited Financial Results (Provisional) for the quarter and half-year ended September 30, 2010.15 Oct · Closure of Buy Back
Panacea Biotec Limited had announced the Buy-Back of its fully paid-up Equity shares of the face value of Re. 1/- each from the existing registered shareholders / beneficial owners of the Equity Shares, other than Promoters Group of the Company, from the Open market through Stock Exchanges by using the electronic trading facilities of the BSE & NSE. The buy back started on 21.07.2010 and the company has bought back the Maximum number of shares i.e. 55,92,000 Equity Shares in terms of the Public Announcement dated June 30, 2010 read with corrigendum dated July 14, 2010, for an aggregate consideration of Rs.109.82 Crores being 85.76% of the Maximum Buy-Back offer size of Rs. 128.05 Crores. In view of the above, the Executive Committee of the Board of Directors of Panacea Biotec Limited had, at its meeting held on today, i.e. 15.10.2010, decided to close the Buy Back offer